| 索拉菲尼治疗肝癌常见不良反应及处理的研究进展 |
| |
| 引用本文： | 张岚(综述),任正刚(审校). 索拉菲尼治疗肝癌常见不良反应及处理的研究进展[J]. 中国肿瘤临床, 2013, 40(20): 1268-1271. DOI: 10.3969/j.issn.1000-8179.20130794 |
| |
| 作者姓名： | 张岚(综述) 任正刚(审校) |
| |
| 作者单位： | 复旦大学附属中山医院肝肿瘤内科（上海市200232） |
| |
| 摘 要： | 索拉菲尼是一种口服多激酶抑制剂。通过作用于Raf激酶直接抑制肿瘤细胞增殖，还可作用于血管内皮生长因子受体1，2，3（VEGFR-1, -2, -3），以及血小板源生长因子受体-β（PDGFR-β）、受体酪氨酸激酶、抑制肿瘤新生血管生成。索拉菲尼通过抑制肿瘤细胞增殖和抗血管生成的双重作用，从而达到抗肿瘤的目的。已被多个国家批准作为首个系统治疗肝细胞肝癌的分子靶向药物。其常见不良反应包括皮肤反应、恶心、腹泻、体质量减轻、高血压等，影响了患者的长期使用依从性，进而影响治疗效果。正确地认识和管理索拉非尼的不良反应则有助于发挥索拉非尼的治疗作用，提高临床效果。本文从索拉菲尼靶向治疗的常见不良反应、发生机制及处理方法等方面进行综述。
|
| 关 键 词： | 原发性肝癌 索拉菲尼 不良反应 |
| 收稿时间： | 2013-05-21 |
Research progress in clinical presentation and management of ad-vent events associated with sorafenib in hepatocellular carcinoma |
| |
| Lan ZHANG , Zhenggang REN. Research progress in clinical presentation and management of ad-vent events associated with sorafenib in hepatocellular carcinoma[J]. Chinese Journal of Clinical Oncology, 2013, 40(20): 1268-1271. DOI: 10.3969/j.issn.1000-8179.20130794 |
| |
| Authors: | Lan ZHANG Zhenggang REN |
| |
| Affiliation: | Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China |
| |
| Abstract: | Sorafenib is a novel oral multikinase inhibitor that inhibits Raf kinase because of its anti-proliferative property. Sorafenib also inhibits receptor tyrosine kinases of multiple proangiogenic factors, such as VEGFR-1/2/3 and PDGFR-β. The combination of both its anti-proliferative and anti-angiogenic properties makes sorafenib an attractive agent in cancer treatment. To date, sorafenib is the only approved systemic treatment for patients with hepatocellular carcinoma. The most common adverse events of this inhibitor included hand–foot skin reactions, nausea, diarrhea, weight loss, and hypertension. These adverse events can severely affect patient compliance, which may negate the effect of therapy. Correct understanding and treatment of these adverse events can improve clinical outcome. This paper discusses the clinical aspect of sorafenib-induced adverse events and the molecular basis behind their toxicity. Recommendations for the management of the adverse effects are also provided. |
| |
| Keywords: | hepatocellular carcinoma sorafenib adverse events |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
